$50M cell and viral vector manufacturing operation backed by Harvard

Harvard University School of Engineering and Applied Sciences
Harvard and several CDMOs are working together to build a cell and viral vector clinical supply facility in the the Boston area. (The Harvard Crimson)

CDMOs are building cell and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and private players is working on a $50 million clinical supply manufacturing facility. 

The facility will help researchers at biotechs, universities and hospitals avoid production bottlenecks that can delay clinical material for more than a year, Harvard said in announcing the project today. 

“Currently, major obstacles to getting new treatments into the clinic revolve around production, specifically the pressure placed on highly skilled contract manufacturers to deliver to labs around the region customized, high-quality cells and viral vectors that meet regulatory standards. Because of the backlog, scientists may need to wait as long as 18 months for the essential products they need to carry out their research,” Harvard said. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices

The not-for-profit facility, to be built in the Greater Boston area, will have eight clean rooms and offer “preferred access … at favorable pricing” the group says. 

Board members will come from Fujifilm Diosynth Biotechnologies, GE Healthcare Life Sciences and Alexandria Real Estate Equities as well as Harvard and the Massachusetts Institute of Technology. Contributing members include the state, a list of hospitals and MilliporeSigma. 

In addition to manufacturing, the group says the facility will provide training and collaboration with top researchers. 

RELATED: Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions'

This project comes even as drugmakers are getting gene therapies approved and contractors are moving fast to buy or boost capacity to serve the growing viral vector and gene therapy fields. Earlier this year, Catalent dropped $1.2 billion to grab viral vector and gene therapy manufacturer Paragon Bioservices, and Thermo Fisher shelled out $1.7 billion to get viral vector producer Brammer Bio. Thermo Fisher now has a facility in Massachusetts, along with others, while Catalent got one in Baltimore. Other contractors are adding or expanding facilities in the U.S., Europe and Asia.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.